ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence.

W.-C. Lee, Y.-C. Wang, C.-H. Cheng, T.-H. Wu, C.-F. Lee, T.-J. Wu, H.-S. Chou, K.-M. Chan.

Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan

Meeting: 2017 American Transplant Congress

Abstract number: 151

Keywords: Hepatitis B, Immunoglobulins (Ig), Liver transplantation

Session Information

Date: Sunday, April 30, 2017

Session Name: Concurrent Session: Liver: Viral Hepatitis

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:42pm-5:54pm

Location: E271a

Related Abstracts
  • Hepatitis B Immune Globulin Withdrawal in HBsAg Positive Liver Transplant Patients.
  • Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence.

Background: Hepatitis B virus (HBV)-related liver disease is the major indication of liver transplantation in Asian countries. Combination of anti-hepatitis B immunoglobulin (HBIg) and anti-viral agents can effectively prevent HBV recurrence. However, HBIg is expensive. How long and what dose of HBIg should be used for prophylaxis of HBV recurrence is still controversial.

Materials and methods: 313 HBV patients who had liver transplantation from 2005 to 2015 and survived for more than 3 months were included in this study. All patients had anti-HBV nucleotide / nucleoside from postoperative day 1. Before 2008 (stage I), HBIg regimen was 10000IU intravenously during an-hepatic phase followed by 2000IU/day for a week. After 2008 (stage II), the peri-operative dosage of HBIg was the same as in stage I. Additionally, the immunoglobulin titers were measured at postoperative month (POM) 1 and 3. If immunoglobulin titer was less than 200IU/ml at POM 1 or less than 30IU/ml at POM 3, HBIg (800IU) were boosted for additional 6 months. Hepatitis B surface antigen (HBs Ag) was measured every 3 months. HBV recurrence was defined as positive for HBs Ag in the serum.

Results: Eighty-one patients who received short-term/low dose HBIg and long-term anti-viral agents after transplantation were included in stage 1. Twenty patients (24.7%) had HBV recurrence. The other 232 patients were included in stage II. 137 patients were not boosted with HBIg. Ninety-five patients were boosted with HBIg due to rapid decline of immunoglobulin titers. Totally, 28 patients (12.1%) in stage II had HBV recurrence which was lower than that in stage I (p = 0.011). For further analysis, 18 patients (18.9%) in boosting group and 10 (7.3%) patients in non-boosting group had HBV recurrence. The patients needing HBIg boosts had a higher HBV recurrent rate than the patients without needing HBIg boosts (p = 0.013). The data implied that the patients with rapid decline of anti-HBV immunoglobulin had high risk for HBV recurrence.

Conclusion: HBV patients need HBIg and anti-viral agents for prophylaxis of HBV recurrence after transplantation. The patients can divided into high and low risky groups according the decline of immunoglobulin titers and received different dosage of HBIg for prophylaxis of HBV recurrence.

CITATION INFORMATION: Lee W.-C, Wang Y.-C, Cheng C.-H, Wu T.-H, Lee C.-F, Wu T.-J, Chou H.-S, Chan K.-M. A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Lee W-C, Wang Y-C, Cheng C-H, Wu T-H, Lee C-F, Wu T-J, Chou H-S, Chan K-M. A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/a-low-dose-anti-hepatitis-b-immunoglobulin-regimen-for-prophylaxis-of-hepatitis-b-recurrence/. Accessed January 19, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.